StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Research analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.

Minerva Neurosciences Price Performance

Shares of NERV stock opened at $2.60 on Wednesday. The company has a market capitalization of $18.18 million, a PE ratio of -0.58 and a beta of 0.14. The firm’s 50-day moving average is $2.76 and its two-hundred day moving average is $2.80. Minerva Neurosciences has a 12 month low of $2.26 and a 12 month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Sell-side analysts forecast that Minerva Neurosciences will post -2.26 EPS for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.